Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Coherus Oncology, Inc. CHRS

Healthcare  —  Biotechnology
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Coherus BioSciences, Inc. (CHRS) Business Profile

Company Overview

Coherus BioSciences, Inc. (NASDAQ: CHRS) is a leading biopharmaceutical company focused on delivering high-quality biosimilar and innovative therapeutics to patients worldwide. Founded in 2010 and headquartered in Redwood City, California, Coherus has established itself as a key player in the biopharmaceutical industry. The company was co-founded by Denny Lanfear, who also serves as the Chairman, President, and Chief Executive Officer. Under his leadership, Coherus has grown significantly, leveraging its expertise in biologics development and commercialization to address unmet medical needs.

Coherus operates with a mission to increase patient access to life-changing therapies by providing affordable and effective treatment options. The company’s leadership team includes experienced professionals from the pharmaceutical and biotechnology sectors, such as Jean-Frederic Viret, Ph.D., Chief Financial Officer, and Vincent Anicetti, Chief Technical Officer. Their collective expertise has been instrumental in driving the company’s strategic initiatives and operational success.

Core Business Segments

Coherus BioSciences focuses on two primary business segments: biosimilars and innovative immuno-oncology therapies.

Biosimilars

Biosimilars are biologic medical products that are highly similar to already approved reference products. Coherus has developed a robust portfolio of biosimilars to address the growing demand for cost-effective alternatives to branded biologics. Key products in this segment include:

  • UDENYCA® (pegfilgrastim-cbqv): A biosimilar to Neulasta®, used to reduce the risk of infection in patients undergoing chemotherapy. UDENYCA® has been a significant revenue driver for Coherus since its launch.
  • YUSIMRY™ (adalimumab-aqvh): A biosimilar to Humira®, approved for the treatment of various autoimmune diseases, including rheumatoid arthritis and Crohn’s disease.
  • CIMERLI™ (ranibizumab-eqrn): A biosimilar to Lucentis®, used for the treatment of retinal diseases such as age-related macular degeneration (AMD).

Immuno-Oncology

Coherus is also expanding its footprint in the immuno-oncology space, focusing on innovative therapies to treat cancer. The company’s pipeline includes:

  • Toripalimab: An anti-PD-1 antibody developed in collaboration with Junshi Biosciences. Toripalimab is being evaluated for multiple indications, including non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma.
  • CHS-006: A novel immuno-oncology candidate targeting TIGIT (T-cell immunoreceptor with Ig and ITIM domains), designed to enhance anti-tumor immune responses.

Business Model

Coherus BioSciences operates on a hybrid business model that integrates the development, manufacturing, and commercialization of biosimilars and innovative therapies. The company generates revenue primarily through product sales, licensing agreements, and strategic collaborations. By focusing on biosimilars, Coherus aims to provide affordable treatment options while maintaining high-quality standards. The company’s immuno-oncology segment represents a long-term growth opportunity, with a pipeline of promising candidates targeting various cancers.

Coherus leverages strategic partnerships to accelerate product development and expand its market reach. For example, its collaboration with Junshi Biosciences has enabled the company to advance its immuno-oncology pipeline. Additionally, Coherus invests in state-of-the-art manufacturing facilities and robust supply chain networks to ensure the consistent delivery of its products.

Strategic Direction

Coherus BioSciences is committed to expanding its product portfolio and market presence. The company’s strategic priorities include:

  • Biosimilar Expansion: Coherus plans to launch additional biosimilars in the coming years, targeting high-value biologics in therapeutic areas such as oncology, immunology, and ophthalmology.
  • Immuno-Oncology Growth: The company is advancing its immuno-oncology pipeline, with a focus on Toripalimab and CHS-006. Coherus aims to establish itself as a leader in the oncology space by delivering innovative therapies that improve patient outcomes.
  • Global Market Penetration: Coherus is exploring opportunities to expand its presence in international markets, leveraging partnerships and regulatory approvals to reach a broader patient population.
  • Sustainability Goals: The company is committed to environmental sustainability and aims to minimize its carbon footprint through efficient manufacturing processes and eco-friendly practices.

Competitive Landscape

Coherus BioSciences operates in a highly competitive biopharmaceutical market. Key competitors in the biosimilar segment include:

  • Amgen Inc.: A global leader in biotechnology, offering a range of biosimilars, including Mvasi® (bevacizumab-awwb) and Kanjinti® (trastuzumab-anns).
  • Sandoz (a Novartis division): A pioneer in biosimilars, with a diverse portfolio targeting oncology, immunology, and endocrinology.
  • Biocon Biologics: An emerging player in the biosimilar market, with a focus on affordable biologics for global markets.

In the immuno-oncology space, Coherus faces competition from established companies such as Merck & Co., Bristol-Myers Squibb, and Roche, which have developed blockbuster therapies like Keytruda®, Opdivo®, and Tecentriq®, respectively.

Risk Factors

Coherus BioSciences faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its biosimilar products, particularly UDENYCA®. Any decline in sales or increased competition could adversely affect revenue.
  • Regulatory Challenges: The development and approval of biosimilars and innovative therapies are subject to stringent regulatory requirements, which can delay product launches.
  • Supply Chain Disruptions: Coherus depends on third-party manufacturers and suppliers for raw materials and finished products. Any disruptions in the supply chain could impact product availability.
  • Intellectual Property Risks: Patent litigation and intellectual property disputes could hinder the company’s ability to commercialize its products.

Recent Developments

Coherus BioSciences has made significant progress in recent months:

  • FDA Approval of YUSIMRY™: In 2023, the company received FDA approval for YUSIMRY™, its biosimilar to Humira®, marking a major milestone in its biosimilar portfolio.
  • Toripalimab Advancements: Coherus continues to advance clinical trials for Toripalimab, with promising results in multiple cancer indications.
  • Strategic Partnerships: The company has strengthened its collaboration with Junshi Biosciences to accelerate the development of its immuno-oncology pipeline.
  • Market Expansion: Coherus has expanded its commercial footprint in the U.S. and is exploring opportunities in Europe and Asia.

Investment Considerations

Strengths

  • Diverse Product Portfolio: Coherus offers a range of biosimilars and innovative therapies, reducing dependence on a single product.
  • Strong Leadership: The company’s experienced management team has a proven track record of success in the biopharmaceutical industry.
  • Growth Potential: Coherus’s immuno-oncology pipeline represents a significant growth opportunity, with multiple candidates in advanced stages of development.

Risks

  • Competitive Pressure: The biosimilar and immuno-oncology markets are highly competitive, with numerous established players.
  • Regulatory Uncertainty: Delays in product approvals or changes in regulatory policies could impact the company’s growth trajectory.
  • Financial Risks: Coherus’s reliance on a few key products for revenue generation exposes it to financial volatility.

Conclusion

Coherus BioSciences, Inc. is well-positioned to capitalize on the growing demand for biosimilars and innovative cancer therapies. With a strong product portfolio, strategic partnerships, and a focus on sustainability, the company is poised for long-term growth. However, investors should carefully consider the risks associated with regulatory challenges, market competition, and financial dependence on key products. Overall, Coherus represents a compelling investment opportunity for those seeking exposure to the biopharmaceutical sector.